{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:13:28Z","timestamp":1793664808215,"version":"4.5.1"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01 BX006247"],"award-info":[{"award-number":["I01 BX006247"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Anti-neutrophil cytoplasmic antibody (ANCA) vasculitides are autoimmune disorders driven by autoantibodies against neutrophil granule proteins, myeloperoxidase (MPO) and proteinase 3, which cause necrotizing small-vessel inflammation with prominent lung and kidney involvement, resulting in pulmonary hemorrhage and glomerulonephritis. Current remission-induction regimens rely on broad immunosuppression and global B cell depletion, which are effective but associated with substantial infection risk and relapse that often necessitates repetitive, long-term treatment. Here, we develop MPO chimeric autoantibody receptor (CAAR) T cells as a target-specific therapy to eliminate MPO-autoreactive B cells. MPO CAAR T cells selectively eliminated anti-MPO BCR-expressing B cell lines\n                    <jats:italic>in vitro<\/jats:italic>\n                    and\n                    <jats:italic>in vivo<\/jats:italic>\n                    . In primary murine autoreactive B cell cultures, MPO CAAR T cells suppressed anti-MPO IgG production without inducing global B cell depletion. Together, these findings support MPO CAAR T cells as a precision approach to eliminate pathogenic B cells in ANCA vasculitis, potentially eliminating the need for generalized humoral immunosuppression.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1814452","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:51:47Z","timestamp":1778219507000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Chimeric autoantibody receptor T cells for targeted depletion of myeloperoxidase-specific anti-neutrophil cytoplasmic antibody-producing B cells"],"prefix":"10.3389","volume":"17","author":[{"given":"Heather M.","family":"Sosnoski","sequence":"first","affiliation":[{"name":"Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Aguilar","sequence":"additional","affiliation":[{"name":"Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawna K.","family":"Brookens","sequence":"additional","affiliation":[{"name":"Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Degaramo","sequence":"additional","affiliation":[{"name":"Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Keane","sequence":"additional","affiliation":[{"name":"Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon-Gyu S.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damodar","family":"Gullipalli","sequence":"additional","affiliation":[{"name":"Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchao","family":"Song","sequence":"additional","affiliation":[{"name":"Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Avery D.","family":"Posey","sequence":"additional","affiliation":[{"name":"Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine","place":["Philadelphia, PA, United States"]},{"name":"Corporal Michael J. Crescenz VA Medical Center","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0272-6386(03)00025-8","article-title":"Outcome of anca-associated renal vasculitis: a 5-year retrospective study","volume":"41","author":"Booth","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200002)43:2<414::AID-ANR23>3.0.CO;2-0","article-title":"Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom","volume":"43","author":"Watts","year":"2000","journal-title":"Arthritis Rheum"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.2.170","article-title":"Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe","volume":"60","author":"Watts","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1998.00807.x","article-title":"Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC\/BCR project for ANCA assay standardization","volume":"53","author":"Hagen","year":"1998","journal-title":"Kidney Int"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198806233182504","article-title":"Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis","volume":"318","author":"Falk","year":"1988","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1994.tb06137.x","article-title":"Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA): a Fc gamma RII-dependent process","volume":"98","author":"Mulder","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1172\/JCI15918","article-title":"Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice","volume":"110","author":"Xiao","year":"2002","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006020108","article-title":"Anti-neutrophil cytoplasmic antibodies and effector CD4+ cells play nonredundant roles in anti-myeloperoxidase crescentic glomerulonephritis","volume":"17","author":"Ruth","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2353\/ajpath.2007.060573","article-title":"Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies","volume":"170","author":"Xiao","year":"2007","journal-title":"Am J Pathol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0002-9440(10)62951-3","article-title":"The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies","volume":"167","author":"Xiao","year":"2005","journal-title":"Am J Pathol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/ki.2008.99","article-title":"Compartment specific expression of dendritic cell markers in human glomerulonephritis","volume":"74","author":"Segerer","year":"2008","journal-title":"Kidney Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2008.191","article-title":"Analysis and classification of B cell infiltrates in lupus and ANCA-associated nephritis","volume":"74","author":"Steinmetz","year":"2008","journal-title":"Kidney Int"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203927","article-title":"Damage in the ANCA-associated vasculitides: long-term data from the European Vasculitis Study Group (EUVAS) therapeutic trials","volume":"74","author":"Robson","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1110548","article-title":"Incidence of serious infections in patients with ANCA-associated vasculitis receiving immunosuppressive therapy: a systematic review and meta-analysis","volume":"10","author":"Vassilopoulos","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab293","article-title":"Severe infections in patients with ANCA-associated vasculitis treated with rituximab","volume":"61","author":"Segelmark","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa699","article-title":"Incidence and predictors of severe infections in ANCA-associated vasculitis: a population-based cohort study","volume":"60","author":"Rathmann","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103713","article-title":"Characteristics and risk factors for infection in patients with ANCA-associated vasculitis: a systematic review and meta-analysis","volume":"24","author":"Luo","year":"2025","journal-title":"Autoimmun Rev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf290","article-title":"CAR-T cells targeting CD19 for the treatment of ANCA vasculitis","volume":"18","author":"Lodka","year":"2025","journal-title":"Clin Kidney J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/ard-2023-224875","article-title":"CD19-targeting CAR T cells protect from ANCA-induced acute kidney injury","volume":"83","author":"Lodka","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.05.016","article-title":"Point-of-care anti-CD19-CAR T cell therapy induces renal remission in refractory myeloperoxidase-antineutrophil cytoplasmic autoantibody-associated vasculitis","volume":"10","author":"Schultze-Florey","year":"2025","journal-title":"Kidney Int Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0285-3","article-title":"Anti-myeloperoxidase antibodies enhance phagocytosis, IL-8 production, and glucose uptake of polymorphonuclear neutrophils rather than anti-proteinase 3 antibodies leading to activation-induced cell death of the neutrophils","volume":"26","author":"Hsieh","year":"2007","journal-title":"Clin Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1992.tb07934.x","article-title":"Activation of normal neutrophils by anti-neutrophil cytoplasm antibodies","volume":"90","author":"Keogan","year":"1992","journal-title":"Clin Exp Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212768","article-title":"Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides","volume":"77","author":"Terrier","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu452","article-title":"Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis","volume":"54","author":"Alberici","year":"2015","journal-title":"Rheumatol (Oxford)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1172\/JCI65292","article-title":"Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis","volume":"123","author":"Roth","year":"2013","journal-title":"J Clin Invest"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2011.04372.x","article-title":"Epitope specificity of myeloperoxidase antibodies: identification of candidate human immunodominant epitopes","volume":"164","author":"Bruner","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1023\/a:1023251001261","article-title":"A panel set for epitope analysis of myeloperoxidase (MPO)-specific antineutrophil cytoplasmic antibody MPO-ANCA using recombinant hexamer histidine-tagged MPO deletion mutants","volume":"18","author":"Tomizawa","year":"1998","journal-title":"J ClinImmunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10040562","article-title":"The enzymatic and non-enzymatic function of myeloperoxidase (MPO) in inflammatory communication","volume":"10","author":"Kargapolova","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016141","article-title":"Infection after CD19 chimeric antigen receptor T cell therapy for large B cell lymphoma: real-world analysis from CIBMTR","volume":"9","author":"Wudhikarn","year":"2025","journal-title":"Blood Adv"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001470","article-title":"Late infectious complications in hematopoietic cell transplantation survivors: a population-based study","volume":"4","author":"Foord","year":"2020","journal-title":"Blood Adv"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006112","article-title":"Impaired immune response to COVID-19 vaccination in patients with B cell Malignancies after CD19 CAR T cell therapy","volume":"6","author":"Dahiya","year":"2022","journal-title":"Blood Adv"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.06.016","article-title":"Long-lived plasma cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow","volume":"43","author":"Halliley","year":"2015","journal-title":"Immunity"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010010034","article-title":"Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis","volume":"22","author":"Bontscho","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02673","article-title":"Long-lived plasma cells in mice and men","volume":"9","author":"Brynjolfsson","year":"2018","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2022.101726","article-title":"Bone marrow derived long-lived plasma cell phenotypes are heterogeneous and can change in culture","volume":"75","author":"Mujtahedi","year":"2022","journal-title":"Transpl Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001030","article-title":"Evaluation of PR3-ANCA status after rituximab for ANCA-associated vasculitis","volume":"25","author":"McClure","year":"2019","journal-title":"J Clin Rheumatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-459289","article-title":"A functional BCR in human IgA and IgM plasma cells","volume":"121","author":"Pinto","year":"2013","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.01.021","article-title":"An antigen-specific chimeric autoantibody receptor (CAAR) NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells","volume":"105","author":"Seifert","year":"2024","journal-title":"Kidney Int"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1562662","article-title":"Chimeric autoantibody receptor T cells specifically eliminate Graves' disease autoreactive B cells","volume":"16","author":"Cheever","year":"2025","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1210147109","article-title":"The immunodominant myeloperoxidase T cell epitope induces local cell-mediated injury in antimyeloperoxidase glomerulonephritis","volume":"109","author":"Ooi","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1994.tb05511.x","article-title":"T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis (Wg)","volume":"98","author":"Brouwer","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s10165-008-0109-1","article-title":"Autoreactive T cell responses to myeloperoxidase in patients with antineutrophil cytoplasmic antibody-associated vasculitis and in healthy individuals","volume":"18","author":"Seta","year":"2008","journal-title":"Mod Rheumatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2013.04.007","article-title":"Myeloperoxidase (Mpo)-specific Cd4+ T cells contribute to Mpo-anti-neutrophil cytoplasmic antibody (Anca) associated glomerulonephritis","volume":"282","author":"Gan","year":"2013","journal-title":"Cell Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1126\/science.aab4077","article-title":"Remote control of therapeutic T cells through a small molecule-gated chimeric receptor","volume":"350","author":"Wu","year":"2015","journal-title":"Science"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.05.014","article-title":"Engineered Car T cells targeting the cancer-associated Tn-glycoform of the membrane mucin Muc1 control adenocarcinoma","volume":"44","author":"Posey","year":"2016","journal-title":"Immunity"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1814452\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:51:48Z","timestamp":1778219508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1814452\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":55,"alternative-id":["10.3389\/fimmu.2026.1814452"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1814452","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"article-number":"1814452"}}